{
      "Rank": 4,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "The dose of infused cells is 10e6 cells/Kg",
            "The dose of infused cells is 4*10e6 cells/Kg"
      ],
      "ArmGroupInterventionName": [
            "Other: Autologous mesenchymal stem cells from adipose tissue.",
            "Other: Autologous mesenchymal stem cells from adipose tissue."
      ],
      "ArmGroupLabel": [
            "Low dose autologous mesenchymal cells",
            "High dose",
            "Placebo Control"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01056471"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple sclerosis who do not respond to treatment."
      ],
      "BriefTitle": [
            "Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER_GOV"
      ],
      "CollaboratorName": [
            "Carlos III Health Institute"
      ],
      "CompletionDate": [
            "June 2015"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Demyelinating Diseases",
            "Nervous System Diseases",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases of the Nervous System"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000056784",
            "D000001927",
            "D000002493"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Leukoencephalopathies",
            "Brain Diseases",
            "Central Nervous System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BC20",
            "All",
            "BC23",
            "BC04",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Immune System Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Neoplasms",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Multiple Sclerosis",
            "Sclerosis",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Secondary Progressive Multiple Sclerosis",
            "Demyelinating Diseases",
            "Autoimmune Diseases of the Nervous System",
            "Demyelinating Autoimmune Diseases, CNS"
      ],
      "ConditionBrowseLeafId": [
            "M11212",
            "M14567",
            "M3781",
            "M11459",
            "M9352",
            "M21466",
            "M6061",
            "M21247",
            "M21251",
            "M27744",
            "M4356",
            "M4894",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Multiple Sclerosis",
            "Sclerosis",
            "Autoimmune Diseases",
            "Neoplasm Metastasis",
            "Immune System Diseases",
            "Multiple Sclerosis, Chronic Progressive",
            "Demyelinating Diseases",
            "Autoimmune Diseases of the Nervous System",
            "Demyelinating Autoimmune Diseases, CNS",
            "Leukoencephalopathies",
            "Brain Diseases",
            "Central Nervous System Diseases",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "high",
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000009103",
            "D000009422",
            "D000020528",
            "D000003711",
            "D000020274",
            "D000020278",
            "D000001327",
            "D000007154",
            "D000012598"
      ],
      "ConditionMeshTerm": [
            "Multiple Sclerosis",
            "Nervous System Diseases",
            "Multiple Sclerosis, Chronic Progressive",
            "Demyelinating Diseases",
            "Autoimmune Diseases of the Nervous System",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases",
            "Immune System Diseases",
            "Sclerosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients diagnosed with Multiple Sclerosis (Poser and McDonald criteria).\nSecondary progressive MS patients with EDSS \u2265 5.5 and \u2264 9.\nPatients with treatment failure defined by: no response to immunomodulators / immunosuppressants, and showing activity in the form of 1 relapse in the last year or 0.5 points in EDSS progression.\nPatients with no MS relapse and no steroid treatment within the month prior to inclusion.\nPatients who give written consent to participate in the study. -\n\nExclusion Criteria:\n\nHistory of current pathology or current laboratory results indicative of any severe disease.\nPacemaker or metallic implants that prevent MR imaging.\nInability to complete questionnaires.\nRefusal to give informed consent.\nPredicted impossibility for a biopsy of at least 30 grams of fat tissue.\nPositive screening test for HIV, Hepatitis B or Hepatitis C.\nHistory of malignancy.\nHaving been in treatment with any investigational drug or have undergone any experimental procedure in the 3 months prior to baseline.\nBody mass index> 40 kg/m2.\nPatients who have been treated with prohibited concomitant medication during the month prior to inclusion in the study.\n\nPregnancy or lactation\n\n-"
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "High dose",
            "Low dose autologous mesenchymal cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.",
            "Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Autologous mesenchymal stem cells from adipose tissue.",
            "Autologous mesenchymal stem cells from adipose tissue."
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Other",
            "Other"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Multiple Sclerosis",
            "Mesenchymal Stem Cells",
            "Autologous"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "August 7, 2015"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "August 4, 2015"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Andalusian Initiative for Advanced Therapies - Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "M\u00e1laga",
            "Sevilla"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Regional Universitario de M\u00e1laga",
            "Hospital Universitario Virgen Macarena"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "29010",
            "41004"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Andalusian Network for Design and Translation of Advanced Therapies"
      ],
      "OrgStudyId": [
            "CMM/EM/2008"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital Regional Universitario Carlos Haya, M\u00e1laga, Spain.",
            "Hospital Universitario Virgen Macarena, Sevilla, Spain"
      ],
      "OverallOfficialName": [
            "Oscar Fernandez Fernandez, MD, PhD",
            "Guillermo Izquierdo Ayuso, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Study Director",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "June 2012"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales."
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Andalusian Molecular Biology and Regenerative Medicine Centre"
      ],
      "SeeAlsoLinkURL": [
            "http://www.cabimer.es"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 2010"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "February 2015"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 26, 2010"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "January 25, 2010"
      ],
      "StudyFirstSubmitQCDate": [
            "January 25, 2010"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}